Swiss Life Asset Management Ltd Sells 21,970 Shares of Biogen Inc. $BIIB

Swiss Life Asset Management Ltd lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 35.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,445 shares of the biotechnology company’s stock after selling 21,970 shares during the period. Swiss Life Asset Management Ltd’s holdings in Biogen were worth $5,666,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC purchased a new stake in Biogen in the 2nd quarter worth about $25,000. Accredited Wealth Management LLC lifted its holdings in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares during the last quarter. WFA of San Diego LLC bought a new position in Biogen during the second quarter worth about $32,000. True Wealth Design LLC boosted its position in Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares during the period. Finally, Bogart Wealth LLC increased its stake in shares of Biogen by 49.8% in the third quarter. Bogart Wealth LLC now owns 313 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 104 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on BIIB shares. Guggenheim boosted their price target on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research report on Monday, February 9th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Biogen in a report on Monday, February 9th. Wolfe Research set a $231.00 price objective on shares of Biogen in a research note on Monday, February 9th. Piper Sandler boosted their target price on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a report on Monday, February 9th. Finally, HSBC increased their target price on Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a research report on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $205.31.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $181.46 on Friday. The company has a 50 day moving average of $184.06 and a 200 day moving average of $168.67. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The stock has a market cap of $26.63 billion, a P/E ratio of 20.60, a P/E/G ratio of 1.44 and a beta of 0.15. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $202.41.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the company posted $3.44 EPS. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts forecast that Biogen Inc. will post 15.83 EPS for the current fiscal year.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: New real‑world data presented at AD/PD show high long‑term persistence on lecanemab, with 78.4% on therapy at 18 months, ~67.3% at 24 months and 94% of clinical‑trial completers entering the open‑label extension — supports ongoing commercial uptake and durability of benefit for LEQEMBI. Article Title
• Positive Sentiment: Late‑breaking data and regulatory momentum for other programs: litifilimab Phase 2 AMETHYST results will be presented at AAD (recent Breakthrough Therapy designation for CLE), and Biogen completed a BIIB080 imaging Phase 1 study — both reinforce pipeline diversification beyond Alzheimer’s. Article Title
• Positive Sentiment: Biogen launched a Phase 3 fumarate study targeting pediatric MS — a potential growth vector for the MS franchise if successful. Article Title
• Neutral Sentiment: Short‑interest reports in recent feeds show anomalous/zero values and NaN changes — appears to be data noise rather than meaningful squeeze risk; monitor reliable exchanges for confirmation. (internal short‑interest entries)
• Negative Sentiment: A securities class action has been certified in the District of Massachusetts on behalf of Biogen purchasers — this increases legal overhang and potential near‑term headline risk. Article Title

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.